We can help you understand and manage immune responses. Our unique solutions for immunology research can save you time, money and risk, whether your objective is basic research, preclinical or clinical development.
January 2019
Mastering Immunity Europe 2019 speakers announced and registration open
September 2018
MHC Pentamers used by team at GSK to study mRNA vaccines that can protect against several Flu strains
Request a Quote
January 2018
ProImmune launches MutaMap™ Mutational Activity Map Service
How does MutaMap™ compare to molecular evolution technologies?
Molecular evolution techniques such as phage display and other phenotype-genotype coupled randomization techniques are most commonly used in the affinity maturation process for monoclonal antibodies and other binding scaffolds. The advantage of these technologies is that they help explore a very large sequence space of combined mutations.
There comes a point however when final decisions have to be made on the implementation of a protein sequence where individual point mutations may be considered in an antibody or therapeutic protein to meet a variety of design objectives. Randomized molecular evolution is not appropriate for this step. Exploring individual point mutations is nothing new, but it has been difficult to carry this step out in very high throughput way, especially where the objective is to clone and express every mutant and then measure its affinity/activity with reasonable accuracy. This is what MutaMap™ can achieve.
Figure 5:Example work flow for pre-clinial protein engineering of therapeutic monoclonal antibody; individual projects may differ.
How long does a MutaMap™ project take?
Our objective is to complete medium size projects of exploring 500-2000 mutations in approximately 8-12 weeks from receiving the customer’s protein sequence. Larger projects will take slightly longer, depending on complexity.
What is the stepwise process for carrying out MutaMap™?
First we will discuss with you the sequence space you want to explore. This may be the known paratope of a protein or the CDR and flanking regions of a monoclonal antibody.
To save time and cost you may not want to explore substituting amino acids into the sequence that are considered highly non-conservative or prone to degradation when exposed. We will also discuss what you know about the binding interaction of your protein with its target, whether you have working immunoassays for this interaction and whether the wild type protein and isolated ligand is available to work with in an immunoassay system. Depending on the nature of the interaction and the binding partners we will ensure that the base assay of binding wild type protein to target works well.
Once these details are agreed and the project is initiated we will run the mutagenesis agreed for each position, express the protein at small scale and carry out the equilibrium binding titration affinity measurement in high throughput.
What will you get?
A final technical report delivered via our secure webserver showing you the affinity or activity determination for the wild type and each mutant with confidence interval. This will be presented in various formats for ease of interpretation, including a standard heatmap.
For customers that want to carry out protein antigenicity studies in parallel, these can be carried out in approximately the same timeframe as the MutaMap™. This means that within a period of approximately 8-12 weeks we will have determined experimentally both the putative T cell epitopes and the MutaMap™ of permitted mutations in your protein sequence. This information can allow you to proceed with much better informed decisions on how to address immunogenicity related issues for your program while addressing simultaneously other developability related design decisions for your sequence.
January 2016
Introducing: ProT2™ MHC Class II Tetramers
Oxford, UK, 14 January 2016
ProImmune, a leader in services for understanding and managing adaptive immune responses, announced today the introduction of ProT2™, a range of Human MHC Class II tetramer reagents for tetramer analyses in the study of antigen-specific CD4+ T cell immune responses. ProImmune’s offering represents the broadest choice of ready to order catalog and custom items in this field and will enable research into CD4+ T cell responses in a variety of disease areas including cancer, infectious diseases, allergy, autoimmunity and transplantation. Another key area for this product range is the detailed study of T cell help in unwanted immune responses to biologics.
CD4+ T cell responses are at the heart of steering the adaptive immune system directing both cytotoxic T cell responses and antibody responses mediated by B cells. ProT2™ MHC Class II Tetramers allow the direct detection and separation of single antigen-specific CD4+T cells accurately by flow cytometry.
Nikolai Schwabe, CEO of ProImmune commented: “By introducing a broad and growing ProT2™ Tetramer product range we intend to give MHC Class II tetramer analysis the emphasis it deserves in the study of CD4+ T cell responses which play such a pivotal role in adaptive immunity across so many disease and treatment modalities.”
ProT2™ Class II MHC Monomer reagents are supported by ProImmune’s expert customer service and application support, helping new users in particular to establish and optimize robust protocols in their own laboratories.
This addition to ProImmune’s class II reagent offering further complements an already extensive range of services for evaluating CD4+ T cell responses, including ProImmune REVEAL® MHC peptide binding assays, CD4+ T cell and DC T cell proliferation assays and standard immune monitoring services through ELISPOT and flow cytometry based assays.
For more information on ProT2™ reagents and their availability, or to place an order, please visit: www.proimmune.com ,email enquiries@www.proimmune.com , or call + 1 888 505 7765 in the United States or + 44 870 042 7279 in other countries.
-ENDS-
Notes to Editors:
About ProImmune - www.proimmune.com
ProImmune’s mission is to be a partner of choice for understanding and managing adaptive immune responses. It does this by offering unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization and immunogenicity testing platform, and products and services for tracking antigen-specific immune responses with state-of-the-art ELISpot and flow cytometry techniques. ProImmune is committed to helping researcher’s achieve success through product innovation, responsive service and focused application support, saving time and money, and reducing risk.
For more information, please contact
At ProImmune:
Jeremy Fry,
Tel: +44 (0) 870 042 7279
Email: enquiries@www.proimmune.com
Media enquiries:
Sarah Jeffery
Zyme Communications Ltd
Tel: +44 (0) 7771 730 919
April 2015
ProImmune Introduces ProSentium™ a Unique Peptide Sequence Database to Investigate T Cell Immune System
Oxford,UK, 14 April 2015 – ProImmune, a leader in services for understanding and managing adaptive immune responses, announced today the introduction of a new antigen database service called ProSentium™, based on in vitro assay results using sequencing mass spectrometry. ProSentium data can show the precise peptide sequences from proteins of interest visible to the body’s own T cell immune system. The data collection covers many high value therapeutic targets and areas including the majority of licensed replacement factor proteins, including clotting factors, replacement enzymes, spanning development areas including oncology, cardiovascular, CNS, immunology, gastroenterology and many orphan diseases.
Under an exclusive or non-exclusive license, the bespoke database service investigates and reports peptide hits against the ProSentium database for a customer’s specific protein or protein family of interest. Results are reported as overlapping nested peptide sets and provide statistically relevant antigen sequence data that can be used to further inform drug development decisions.
Nikolai Schwabe, CEO of ProImmune commented: “ProSentium supports pivotal decision making in drug design and development with the physical evidence required for game changing approaches that target or interact with the immune system. Through our service offering, we are delighted that we can offer this ground-breaking resource to researchers so they can better understand the body’s immune response and bring new therapies to patients. ”
T cells play a critical role in all immune responses, including in fighting infections, cancer and in autoimmunity and in unwanted drug reactions. To understand T cell responses, it is crucial to understand the specific peptide antigens that the immune system recognizes and are presented on the cell surface of both normal and diseased cells. ProSentium data can be readily analyzed and reported, and is fully compatible with ProImmune’s in vitro assay services which can be combined to help investigators gain a more complete understanding of relevant immune responses at a molecular level.
For more information on ProSentium please visit: www.proimmune.com, email enquiries@www.proimmune.com , or call +1 888 505 7765 in the United States or +44 870 042 7279 inother countries.
More on ProSentium™
ProImmune’s mission is to be a partner of choice for understanding and managing immune responses. It does this by offering unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen characterization and immunogenicity testing platform, and products and services for tracking specific immune responses. ProImmune is committed to helping researcher’s achieve success through product innovation, responsive service and focused application support, saving time and money, and reducing risk.
Jeremy Fry
14 Dec 2020 To 16 Dec 2020
Antibody Engineering & Therapeutics, Virtual
“Application of Immunogenicity Prediction and Mitigation for Biotherapeutic Development”
“Understanding SARS-CoV-2 Specific T cell Response During COVID-19 Convalescence”
“Immunogenicity in the Time of COVID-19”
“SARS-CoV-2 specific T cell Immunity in COVID 19, SARS and Uninfected Controls”
“Measuring Host-vs-CAR-T Immune Responses”
“Immunogenicity risk assessment of peptide-related impurities: Current Strategies & its Challenges”
“Effects of codon optimization on biotherapeutics: Implications for immunogenicity”
“In Silico and In Vitro Tools to Investigate Increased Immunogenicity Incidence Observed in Combination Therapies”
“Dissecting Melanoma Neoantigen Immunity”
“Assessment of MHC class II-restricted epitope prediction in silico”
“T Cell Coinhibitory Pathways and Cancer Immunotherapy: Roles of the PD-1 pathway in controlling tolerance and tumor immunity”
“Host microbe interactions in the intestine: New therapeutic strategies in IBD”
“Tregs -ready for the clinic”
“Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”
“Assessing and Modulating Immune Responses to AVV Vectors in Humans”
“Use of the MHC Associated Peptide Proteomic (MAPPs) assay to understand clinical outcomes associated with the use of Factor VIII in the treatment of Hemophilia A”
“Short-term therapeutic intervention for the therapeutic harnessing of tolerance mechanisms”
“Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”
“Specificity and phenotype of pre-existing T cells against therapeutic proteins”
“Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children”
“An integrated approach to managing immunogenicity risk and drug immune modulation”
“Optimizing Adoptive T cell Therapies”
“Immunogenicity Risk Assessment Tool Box for Biologics Drug Development”
“Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”
“Epitope identification and clinical immune monitoring in IO programs”
“B Cell Selection and Survival: First Order Consideration for Immunogenicity”
“De novo generation of tumor specific T cell responses utilizing a novel oncology driven delivery platform”
“Identification and Characterization of Hepatitis B Virus-Specific T cells”
“Tumour Reactive T cell Functional Programming in Human Cancer”
“Tracking Dynamic Changes in Tumour Infiltrating Lymphocytes 𝘪𝘯 𝘷𝘪𝘷𝘰”
“Harnessing Endogenous Antiviral T cell Responses for Control of Cancer”
“Ion channel decorated liposomes: therapeutic potential and immunogenicity”
“Syntekabio Bio’s Use of Genomic Big Data in Neoantigen Prediction and Discovery”
“Precision Medicine in Transplantation – immune monitoring for the discrimination of GVHD, rejection and CMV infection”
“Phosphopeptide NeoAntigens for Tumor Immunity: Novel therapeutic options”
“Heterologous prime-boost approaches to CD8+ T cell induction”
“Next Generation approaches to enhance the efficacy of SPEAR T-cells”
“Format and Interpretation of a Drug Tolerant Approach for Measuring Circulating Immune Complex and Free Anti-Drug Antibodies in Preclinical Studies”
“Neo-antigenic Potential of Chromosomal Rearrangements in Mesothelioma”
“The Challenge of Measuring Antigenic Diversity”
“Implementation of risk assessment outputs to drive clinical immunogenicity strategy and regulatory filing-related activities”
“Detailed Characterization of Immune Bio-Markers in Cancer Patients”
“Using peptide-based assays to improve the laboratory diagnosis of Lyme disease”
“Antiviral T cells derived from the naïve population for patients post-transplant”
Dr Jeremy Fry provides a summary of ProImmune’s REVEAL and ProVE® service, the rapid epitope discovery system.
Dr Andrew Waller provides an overview of the Pro5 Pentamer technology and the benefits of using MHC pentamers to detect specific CD8 T Cell populations in your research.
Dr Heather Hensler introduces ProArray Ultra®, the high-throughput peptide and protein microarray assay service.
Dr Briana Betz explains the importance of understanding the HLA types of your study cohort, and how ProImmune can help you.
Dr Nikolai Schwabe introduces the ProPresent antigen presentation assay and some of its applications in the field of immunogenicity.
Managing immunogenicity risk should be a core focus in drug development. ProImmune’s CEO Nik Schwabe explains why.
Pentamer Handbook
thinkpeptides Peptide Ebook
Dr. Navapon Techakriengkrai Chulalongkorn University, Thailand
"I outsourced my tissue typing to ProImmune because they provide me with the fastest service at the best price. Since the main theme of my research is on T cell immunology, HLA-type is inevitably needed. The customer service from ProImmune is of the best quality. Their typing service allowed me to unambiguously resolve the HLA type of many of my samples."
Dr. Jennifer Kirchherr Duke Human Vaccine Institute, North Carolina, USA
"We have a programme of clinical studies and it is important for our researchers to be able to correlate the immune responses they observe with HLA type. We looked at a range of companies offering tissue typing, and also at using an on-campus typing facility, and we found that ProImmune were able to offer us the best pricing and turnaround time. We now send them regular batches of samples to type. They have been wonderfully easy to work with, if we ask anything they get right back to us and overall it has been a really good experience."
Prof. Raymond Dattwyler New York Medical College, New York, USA
Prof. Dattwyler used ProImmune's B cell Linear Epitope Mapping Service to discover the linear epitopes present in two different proteins. "I was really happy with the way that these guys took the trouble to adjust my quote so that I had the best assay design for the lowest price. They were really easy to work with, always replied to my questions, and delivered the report on my project on schedule as promised. It's great that I've been able to go back to them and order my new epitopes as custom peptides for follow on work, and I'm going to revisit my validated epitopes with ProImmune's help and get some really fine mapping of antibody binding to these sequences."
ProImmune REVEAL & ProVE® Epitope Discovery
Model Antigens
HLA Tissue Typing
CD1d Tetramers
Listeria
ProMap® T Cell Proliferation Assay
Pro5® MHC Class I Pentamers
